J. Joseph Melenhorst

4 ta ish

University of Pennsylvania

1. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

2. CRISPR-engineered T cells in patients with refractory cancer

   Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

   MaqolaOAOchiq kirish20203 iqtibos

   ABIABI:AkademIndex/2026.other.102870

3. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493

4. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

   Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons +35

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.475807